Evidence map›Paper›PMID 42905847›Full record

ArticleScience advances2026

Furan fatty acids reprogram hepatic lipid metabolism via acyl-CoA conjugates in obesity.

Matias M Vazquez, Sonia R Salvatore, Pascal Rowart, Sumit Kumar Anand, Nicole Colussi, Marco Fazzari, Aidan R Cole, Cristina Espinosa-Diez, Soma Jobbagy, Jia-Jun Liu and 13 more

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Matias M VazquezDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9162-3008
Sonia R SalvatoreDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9942-3905
Pascal RowartDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-4210-2713
Sumit Kumar AnandDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana, USA.ORCID 0000-0003-3719-0744
Nicole ColussiDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Marco FazzariDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-4051-4431
Aidan R ColeDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9647-0848
Cristina Espinosa-DiezCenter for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, USA.ORCID 0000-0002-5868-3807
Soma JobbagyDepartment of Pathology and Laboratory Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
Jia-Jun LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0009-0001-3677-613X
Jianhua LuoPittsburgh Liver Research Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3189-4225
Delphine GomezDepartment of Medicine, Division of Cardiology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3880-6961
Silvia LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-1840-9520
Carsten SkarkeInstitute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-5145-3681
Fiona M BelloDepartment of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9516-7318
Michael J JurczakDepartment of Medicine, Division of Endocrinology and Metabolism, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-6335-6915
Kacey J PrenticeDepartment of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.ORCID 0009-0003-9653-2828
Michael B WheelerDepartment of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.ORCID 0000-0002-7480-7267
Mohamed TrebakDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-6759-864X
Nicholas K H KhooDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Oren RomDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana, USA.ORCID 0000-0002-9272-086X
Fei ChangDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-3724-2455
Francisco J SchopferDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9526-695X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dietary fish oil (FO) and omega-3 fatty acids are associated with cardiometabolic benefits, yet their molecular mediators remain incompletely defined. Furan fatty acids (FuFAs), a distinct lipid class enriched in FO, have emerged as potential regulators of metabolic health. Here, we identify and quantify FuFA species in prescription omega-3 formulations and natural fish oils, and synthesize structurally engineered analogs designed to isolate antioxidant activity and β-oxidation susceptibility from FuFA bioactivity. In a diet-induced obesity mouse model, both natural and synthetic FuFAs reduced fat accumulation and inflammatory markers, while 11U3-2M additionally produced significant improvement in glucose tolerance, dyslipidemia, and hepatic steatosis. The superior activity of 11U3-2M reflects the stable accumulation of its acyl-CoA conjugate that activates peroxisome proliferator-activated receptor alpha (PPARα) signaling and allosterically inhibits acetyl-CoA carboxylases (ACCs) to reprogram hepatic lipid metabolism. These findings position FuFAs as functional dietary lipids contributing to fish oil's metabolic effects and define fatty acid structural determinants that govern hepatic metabolic activity.

Indexed as

Acyl Coenzyme AFatty AcidsFuransLipid MetabolismLiverObesityAnimalsDisease Models, AnimalFatty Acids, Omega-3Fish OilsMicePPAR alphaAcyl Coenzyme AFatty AcidsFatty Acids, Omega-3Fish OilsFuransPPAR alpha

Identifiers

PMID42905847
PMCPMC13686009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.